The Pharmaceuticals Pricing Board (Lääkkeiden hintalautakunta) Hila has scheduled new horizon scanning sessions for May 2026 following oversubscription to previous events. This expansion allows the regulator to manage high industry demand for early-stage dialogues regarding products expected to enter the Finnish market.
The consultations will take place on 5 May 2026 and – if required – 26 May 2026. Hila prioritises discussions on products that are most topical for the national healthcare system. During the 30-minute meetings, companies may present pipeline information to the chairs of the Pharmaceuticals Pricing Board and the expert group, board members, and the secretariat. These data are used solely for internal budgetary and clinical planning and do not constitute formal guidance for the subsequent reimbursement application process.
The scope of the hearings includes new medicinal products and new indications for existing therapies. Hila will not discuss products that have already entered the formal national application process. This separation ensures the scanning remains a strategic intelligence exercise rather than a procedural negotiation.
Manufacturers must register their interest by 10 March 2026. Each submission must include a brief description of the presentation and an estimated timeline for the reimbursement filing. Hila will notify the selected participants by 31 March 2026.
This initiative indicates a move towards more proactive pipeline management by the Finnish payer. By formalising these early-stage dialogues, Hila seeks to reduce information asymmetry between the regulator and industry. This foresight facilitates more predictable decision-making for high-cost innovations.
Source: Pharmaceuticals Pricing Board
Link: Hintalautakunnan horisonttiskannausta koskevat kuulemistilaisuudet lääkeyrityksille (Pharmaceuticals Pricing Board's horizon scanning hearing for pharmaceutical companies)
Date: 10 February 2026
